TCRR - TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T.
In order to participate in the conference call, please register at https://bit.ly/3BTJ9Z7 . Participants can register via this link up to ten minutes prior to start time. The webcast and presentation will be made available on the TCR 2 Therapeutics website in the Investors section under Events at investors.tcr2.com/events . Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
About TCR 2 Therapeutics
TCR 2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC ® -T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR 2 , please visit www.tcr2.com.
Investor and Media Contact:
Carl Mauch
Senior Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com